The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 1×
“Accordingly, preclinical models in psychiatry have evolved from 'reverse translation' in which clinical observation in patients has led to the development of behavioural models in which validated drugs exhibit predictive pharmacological response”
BackgroundNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies
Braff, D. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140081011 · Cited by 1,309
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,290
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Discovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 818
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Roberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
(2000) · PubMed · Cited by 685
Marambaud, P. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.1948 · Cited by 685
NXY-059 for Acute Ischemic Stroke
Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test
Lipska, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00137-8 · Cited by 650
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 645
Learning versus confirming in clinical drug development*
Sheiner, L. B. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90160-0 · Cited by 633
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Human EEG gamma oscillations in neuropsychiatric disorders
Herrmann, C. S., & Demiralp, T. (2005) · Clinical Neurophysiology · doi:10.1016/j.clinph.2005.07.007 · Cited by 599
Johnson, N. A., Jahng, G.-H., Weiner, M. W., Miller, B. L., Chui, H. C., Jagust, W. J., Gorno-Tempini, M. L., & Schuff, N. (2005) · Radiology · doi:10.1148/radiol.2343040197 · Cited by 587
Social Functioning in Depression: A Review
Hirschfeld, R. M. A., Montgomery, S. A., Keller, M. B., Kasper, S., Schatzberg, A. F., Moller, H.-J., Healy, D., Baldwin, D., Humble, M., Versiani, M., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0405 · Cited by 586
Preclinical models: status of basic research in depression
Nestler, E. J., Gould, E., & Manji, H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01405-1 · Cited by 558
Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets
Klein, W. L. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00050-5 · Cited by 545
A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development
Kamiya, A., Kubo, K.-I., Tomoda, T., Takaki, M., Youn, R., Ozeki, Y., Sawamura, N., Park, U., Kudo, C., Okawa, M., et al. (2005) · Nature Cell Biology · doi:10.1038/ncb1328 · Cited by 531
Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H.-C., Xu, G., Koliatsos, V. E., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-05.2005 · Cited by 521
Mohs, R. C., Knopman, D. S., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L. A., Geldmacher, D., Clark, C., et al. (1997) · PubMed · Cited by 487
Cognitive reserve and the neurobiology of cognitive aging
Whalley, L. J., Deary, I. J., Appleton, C. L., & Starr, J. M. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.05.001 · Cited by 460
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459
Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., Debnath, M. L., Holt, D. P., Huang, G.-F., Shao, L., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2990-05.2005 · Cited by 377
Janssen, P. A., Cj, N., & Schellekens, K. H. L. (1965) · PubMed · Cited by 348
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke
Paul, R., Zhang, Z. G., Eliceiri, B. P., Jiang, Q., Boccia, A. D., Zhang, R. L., Chopp, M., & Cheresh, D. A. (2001) · Nature Medicine · doi:10.1038/84675 · Cited by 342
Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Ferrante, R., Kowall, N., & Richardson, E. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-12-03877.1991 · Cited by 306
Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294
Are mitochondria critical in the pathogenesis of Alzheimer's disease?
Reddy, P. H., & Beal, M. F. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.03.004 · Cited by 289
Booth, B., & Zemmel, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1384 · Cited by 278
Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
Rupniak, N. M. J., & Kramer, M. S. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01396-6 · Cited by 276
Biological markers for therapeutic trials in Alzheimer’s disease
Frank, R. A., Galasko, D., Hampel, H., Hardy, J., de Leon, M. J., Mehta, P. D., Rogers, J., Siemers, E., & Trojanowski, J. Q. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00002-2 · Cited by 252
Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease
Praticò, D., & Sung, S. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6209 · Cited by 229
Innovative approaches for the development of antidepressant drugs: Current and future strategies
Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X., Malberg, J. E., & Rosenzweig-Lipson, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.590 · Cited by 228
Self-citationDopaminergic Modulation of Visual Attention and Working Memory in the Rodent Prefrontal Cortex
Chudasama, Y., & Robbins, T. W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300490 · Cited by 225
Risch, N., & Botstein, D. (1996) · Nature Genetics · doi:10.1038/ng0496-351 · Cited by 214
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry
Leow, A. D., Klunder, A. D., Jack, C. R., Toga, A. W., Dale, A. M., Bernstein, M. A., Britson, P. J., Gunter, J. L., Ward, C. P., Whitwell, J. L., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.12.013 · Cited by 214
Brunton, V. G., Avizienyte, E., Fincham, V. J., Serrels, B., Metcalf, C. A., Sawyer, T. K., & Frame, M. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1949 · Cited by 213
Molecular biology and genetics of Alzheimer's disease
St George-Hyslop, P. H., & Petit, A. (2005) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2004.10.013 · Cited by 210
King, M. V., Sleight, A. J., Woolley, M. L., Topham, I. A., Marsden, C. A., & Fone, K. C. F. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.03.012 · Cited by 197
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Crystal Structure of Memapsin 2 (β-Secretase) in Complex with an Inhibitor OM00-3
Hong, L., Turner, R. T., Koelsch, G., Shin, D., Ghosh, A. K., & Tang, J. (2002) · Biochemistry · doi:10.1021/bi026232n · Cited by 190
Cutting the cost of drug development?
Rawlins, M. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1347 · Cited by 187
Gene Dosage of the Amyloid β Precursor Protein in Alzheimer's Disease
Podlisny, M. B., Lee, G., & Selkoe, D. J. (1987) · Science · doi:10.1126/science.2960019 · Cited by 175
Will the Genomics Revolution Revolutionize Psychiatry?
Merikangas, K. R., & Risch, N. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.625 · Cited by 172
Alzheimer's patients engage an alternative network during a memory task
Pariente, J., Cole, S., Henson, R., Clare, L., Kennedy, A., Rossor, M., Cipoloti, L., Puel, M., Demonet, J. F., Chollet, F., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20653 · Cited by 161
The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia
Braff, D. L., & Light, G. A. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.2/dlbraff · Cited by 160
Harrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00227-6 · Cited by 152
Self-citationVersijpt, J. J., Dumont, F., van Laere, K. J., Decoo, D., Santens, P., Audenaert, K., Achten, E., Slegers, G., Dierckx, R., & Korf, J. (2003) · European Neurology · doi:10.1159/000070857 · Cited by 152
Papadopoulos, C. M., Tsai, S., Cheatwood, J. L., Bollnow, M. R., Kolb, B. E., Schwab, M. E., & Kartje, G. L. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhi132 · Cited by 147
Impact of genomics on drug discovery and clinical medicine
Emilien, G. (2000) · QJM · doi:10.1093/qjmed/93.7.391 · Cited by 147
Association of Risperidone Treatment Response With a Polymorphism in the 5-HT2A Receptor Gene
Lane, H., Chang, Y., Chiu, C., Chen, M., Hsieh, M.-H., & Chang, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1593 · Cited by 144
Performance of the marmoset monkey on computerized tasks of attention and working memory
Spinelli, S., Pennanen, L., Dettling, A. C., Feldon, J., Higgins, G. A., & Pryce, C. R. (2004) · Cognitive Brain Research · doi:10.1016/j.cogbrainres.2003.11.007 · Cited by 142
Schechter, L. E., Smith, D. L., Rosenzweig-Lipson, S. J., Rizzo, S. J. S., Dawson, L. A., Marquis, K. L., Jones, D., Piesla, M. J., Andree, T. H., Nawoschik, S. P., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086363 · Cited by 132
Self-citationLow Baseline Bispectral Index of the Electroencephalogram in Patients with Dementia
Renna, M., Handy, J. M., & Shah, A. K. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000059223.78879.0f · Cited by 130
Substance P Receptor Antagonists in Psychiatry: Rationale for Development and Therapeutic Potential
Herpfer, I., & Lieb, K. (2005) · CNS Drugs · doi:10.2165/00023210-200519040-00001 · Cited by 123
Lewczuk, P., Esselmann, H., Bibl, M., Beck, G., Maler, J. M., Otto, M., Kornhuber, J., & Wiltfang, J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:115 · Cited by 120
Carlsson, A., Jonason, J., Lindqvist, M., et al. (1969) · Brain Research · doi:10.1016/0006-8993(69)90013-4 · Cited by 115
The History of the Psychopharmacology of Schizophrenia
Lehmann, H. E., & Ban, T. A. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200205 · Cited by 109
Roses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 109
Jacobsen, J. S., Reinhart, P. H., & Pangalos, M. N. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.612 · Cited by 102
Self-citationDepressions following reserpine: a reevaluation.
Goodwin, F. K., & Bunney, W. E. (1971) · PubMed · Cited by 97
Role of the Bispectral Index in Sedation Monitoring in the ICU
LeBlanc, J. M., Dasta, J. F., & Kane‐Gill, S. L. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1e491 · Cited by 91
Skelton, R. W., Ross, S., Nerad, L., & Livingstone, S. A. (2006) · Brain Injury · doi:10.1080/02699050500456410 · Cited by 80
Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503
Rosenzweig-Lipson, S. J., Zhang, J., Mazandarani, H., Harrison, B. L., Sabb, A. L., Sabalski, J. E., Stack, G., Welmaker, G., Barrett, J. E., & Dunlop, J. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.052 · Cited by 78
Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease
Dominguez, D. I., & Strooper, B. D. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02038-2 · Cited by 75
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
Meltzer, H. Y., Davidson, M., Glassman, A. H., & Vieweg, W. V. R. (2002) · PubMed · Cited by 74
Dawson, D. A., Wadsworth, G., & Palmer, A. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03269-8 · Cited by 72
Clinical experience with substance P receptor (NK1) antagonists in depression.
Ranga, K., & Krishnan, R. (2002) · PubMed · Cited by 68
Komater, V. A., Browman, K. E., Curzon, P., Hancock, A. A., Decker, M. W., & Fox, G. B. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1431-0 · Cited by 59
Spinelli, S., Ballard, T. M., Gatti‐McArthur, S., Richards, G. J., Kapps, M., Woltering, T. J., Wichmann, J., Stadler, H., Feldon, J., & Pryce, C. R. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2126-x · Cited by 58
Drug Interactions with Cholinesterase Inhibitors
Defilippi, J. L., & Crismon, M. L. (2003) · Drugs & Aging · doi:10.2165/00002512-200320060-00003 · Cited by 51
Pangalos, M. N., Jacobsen, S. J., & Reinhart, P. H. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330553 · Cited by 48
Self-citationWolf, C. R., & Smith, G. C. (1999) · PubMed · Cited by 44
23 On the resolution and feasibility of genome scanning approaches
Terwilliger, J. D. (2001) · Advances in genetics · doi:10.1016/s0065-2660(01)42032-3 · Cited by 39
Hornig, C. R., Busse, O., Buettner, T. L., Dorndorf, W., Agnoli, A. L., & Akengin, Z. (1985) · Stroke · doi:10.1161/01.str.16.2.268 · Cited by 39
Francis, P. T., Pangalos, M. N., Stephens, P. H., Bartlett, J. R., Bridges, P. K., Malizia, A. L., Neary, D., PROCTER, A. W., Thomas, D. J., & Bowen, D. M. (1993) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.1.80 · Cited by 38
Self-citationKlimas, M. T. (2002) · Molecular Imaging and Biology · doi:10.1016/s1536-1632(02)00017-3 · Cited by 38
Mouse Models of Human Neurodegenerative Disorders: Requirements for Medication Development
Bloom, F. E., Reilly, J. F., Redwine, J. M., Wu, C.-C., Young, W. G., & Morrison, J. H. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.185 · Cited by 37
Classical conditioning in patients with Alzheimer's disease: A multiday study.
Solomon, P. R., Brett, M., Groccia-Ellison, M. E., Oyler, C., Tomasi, M., & Pendlebury, W. W. (1995) · Psychology and Aging · doi:10.1037//0882-7974.10.2.248 · Cited by 36
NXY-059: Review of Neuroprotective Potential for Acute Stroke
Fong, J. J., & Rhoney, D. H. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1e636 · Cited by 34
Season of birth and obstetrical complications in schizophrenics
Kinney, D. K., Levy, D. L., Yurgelun-Todd, D. A., Medoff, D., Lajonchere, C., & Radford-Paregol, M. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90040-x · Cited by 33
(2006) · Nature · doi:10.1038/444532a · Cited by 33
O’Toole, M. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1531 · Cited by 29
Zhang, L., Lee, J., Song, L., Sun, X., Shen, J., Terracina, G., & Parker, E. M. (2005) · Biochemistry · doi:10.1021/bi0481500 · Cited by 25
Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging
Kung, M., Zhuang, Z., Hou, C., & Kung, H. F. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:049 · Cited by 20
Craniofacial dysmorphology in Swedish schizophrenia patients
Kelly, B. D., Lane, A., Agartz, I., Henriksson, K., & McNeil, T. F. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00473.x · Cited by 17
Diabetes: Assessing the pipeline
Lebovitz, H. E. (2006) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2006.01.007 · Cited by 16
Arterial Hypertension and Stroke Prevention: An Update
Bornstein, N. M., Silvestrelli, G., Caso, V., & Parnetti, L. (2006) · Clinical and Experimental Hypertension · doi:10.1080/10641960600549405 · Cited by 14
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7
Appraisal of AβPP Transgenic Mice as Models for Alzheimers Disease Amyloid Cascade
Roher, A. E., & Kokjohn, T. A. (2003) · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents · doi:10.2174/1568013033358590 · Cited by 5
The potential utility of transgenic mice harboring β-amyloid precursor protein
Schenk, D. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00081-o · Cited by 3
Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Self-citationAnalysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
Rihel, J., Prober, D. A., Arvanites, A., Lam, K., Zimmerman, S., Jang, S., Haggarty, S. J., Kokel, D., Rubin, L. L., Peterson, R. T., et al. (2010) · Science · doi:10.1126/science.1183090 · Cited by 778
Metadata
- Authors
- Pangalos, M. N., Schechter, L. E., & Hurko, O.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-07
- Volume
- 6
- Issue
- 7
- Pages
- 521-532
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2094091345
- Cited by
- 336
- References
- 123
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.